ClinicalTrials.gg
CompletedNCT05523765NEPTUNEUpdated Jul 25, 2025

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

A Phase 2 interventional study of Brepocitinib in Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis and Non-infectious Pan Uveitis, sponsored by Priovant Therapeutics, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Priovant Therapeutics, Inc. · Phase 2, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.

Enrollment
45th of 100
26 · median 19
Started
2022
with 8 others
Phase 2
28 of 139
none open now
Registered
129th of 139
by date

Among the 139 studies in Uveitis with a site in United States, this one is the 45th largest by enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2022, is one of 28 in phase 2, and was the 129th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Uveitis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

03

Conditions studied

  • Non-infectious Intermediate Uveitis
  • Non-infectious Posterior Uveitis
  • Non-infectious Pan Uveitis

Browse trials for

Keywords

  • Brepocitinib
  • PF-06700841
  • uveitis
  • NIU
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subjects (18-74 years old)
  2. Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis).
  3. Active uveitic disease as defined by the presence of at least 1 of the following parameters in at least 1 eye, as determined by the investigator:

    1. Active, inflammatory chorioretinal and/or retinal vascular lesion; OR
    2. ≥2+ vitreous haze grade (NEI/SUN criteria).
  4. Receiving up to one non-, non-biologic, immunomodulatory therapy
  5. Weight > 40 kg with a \< 40 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Has isolated anterior uveitis.
  2. Has confirmed or suspected current diagnosis of infectious uveitis
  3. History of:

    • Any lymphoproliferative disorder
    • Active ;
    • History of cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
  4. At risk of thrombosis and cardiovascular disease
  5. Have a high risk for herpes zoster reactivation
  6. Have active or recent infections

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Brepocitinib Dose Level 1 by mouth (PO) once daily (QD)

    Drug: Brepocitinib

  • Experimental
    Brepocitinib Dose Level 2 by mouth (PO) once daily (QD)

    Drug: Brepocitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Safety assessments will consist of monitoring and recording all adverse events (AEs) and SAEs, laboratory evaluation for hematology, blood chemistry, and urinalysis; vital signs; electrocardiograms (ECGs); and physical examinations. The investigator will determine whether the change is clinically meaningful.

    Time frame: Screening up to 28 days after the last dose of study drug at 52 weeks

Secondary outcomes

  1. Proportion of participants meeting treatment failure criteria on or after Week 6 up to Week 24

    Time frame: 24 weeks

07

Study locations

15 sites
  • Clinical Trial Site
    Los Angeles, California 90095, United States
  • Clinical Trial Site
    Palo Alto, California 94303, United States
  • Clinical Trial Site
    Pasadena, California 91107, United States
  • Clinical Trial Site
    Lakewood, Colorado 80228, United States
  • Clinical Trial Site
    Waltham, Massachusetts 02451, United States
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
  • Clinical Trial Site
    Palisades Park, New Jersey 07650, United States
  • Clinical Trial Site
    Durham, North Carolina 27710, United States
  • Clinical Trial Site
    Winston-Salem, North Carolina 27157, United States
  • Clinical Trial Site
    Eugene, Oregon 97401, United States
  • Clinical Trial Site
    Nashville, Tennessee 37203, United States
  • Clinical Trial Site
    Bellaire, Texas 77401, United States
  • Clinical Trial Site
    Katy, Texas 77494, United States
  • Clinical Trial Site
    Plano, Texas 75075, United States
  • Clinical Trial Site
    Salt Lake City, Utah 84107, United States
08

References and documents

Individual participant data

Plan to share: Yes — Priovant Therapeutics will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) from eligible studies upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Data requests will be reviewed and approved on the basis of scientific merit.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The data will be made available within 24 months after study completion and will be accessible for a time frame appropriate for the approved proposal.

Access criteria: Access will be provided following review and approval of a research proposal and execution of a Data Sharing Agreement (DSA). Further details on Priovant Therapeutics' data sharing criteria and process for requesting access can be obtained by emailing info@priovanttx.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2024, 20 months.

Of 17 phase 2 interventional studies under Uveitis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 37. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 31, 2022
StartActual
Nov 14, 2022
Primary completionActual
Jul 30, 2024
CompletionActual
Jul 30, 2024
Results delay requested
Jul 22, 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05523765
Lead sponsor
Priovant Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Nov 14, 2022
Primary completion
Jul 30, 2024
Completion
Jul 30, 2024
Last update
Jul 25, 2025

Study contacts

Brendan Johnson, PhD
study director · SVP, Early Development

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion